CliffBio
small molecule

FLOLIPID

SIMVASTATIN

Loss of exclusivityFebruary 2030latest FDA-listed patent expiry
CompanySalerno →See this company's full patent-cliff portfolio

Drug detail

Brand nameFLOLIPID
Active ingredientSIMVASTATIN
Strength40MG/5ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalApril 2016
Marketing statusRX

Listed patents

PatentExpiresType
9597289February 2030product
10300041April 2027product

More from Salerno

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

FLOLIPID patent cliff — loss of exclusivity February 2030 | CliffBio